Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Journey Medical (DERM) over the last 5 years, with Q3 2025 value amounting to $7.0 million.

  • Journey Medical's Cash from Financing Activities rose 249387.76% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year decrease of 1627.97%. This contributed to the annual value of $17.0 million for FY2024, which is 45372.61% up from last year.
  • As of Q3 2025, Journey Medical's Cash from Financing Activities stood at $7.0 million, which was up 249387.76% from $165000.0 recorded in Q2 2025.
  • Over the past 5 years, Journey Medical's Cash from Financing Activities peaked at $31.8 million during Q4 2021, and registered a low of -$13.1 million during Q2 2023.
  • For the 5-year period, Journey Medical's Cash from Financing Activities averaged around $4.9 million, with its median value being $3.6 million (2025).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 1189099.1% in 2023, then skyrocketed by 304807.69% in 2024.
  • Journey Medical's Cash from Financing Activities (Quarter) stood at $31.8 million in 2021, then crashed by 97.02% to $948000.0 in 2022, then soared by 1926.37% to $19.2 million in 2023, then plummeted by 44.72% to $10.6 million in 2024, then tumbled by 33.72% to $7.0 million in 2025.
  • Its last three reported values are $7.0 million in Q3 2025, $165000.0 for Q2 2025, and $3.6 million during Q1 2025.